Press release
Investigation announced for Long-Term Investors in shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares.
Investors who are current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: APLS stocks follows a lawsuit filed against Apellis Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: APLS stocks, concerns whether certain Apellis Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Delaware the plaintiff alleges that the Defendants misrepresented and/or failed to disclose that the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections, that as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors, and that therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.
Those who purchased shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) here
News-ID: 3279534 • Views: …
More Releases from Shareholders Foundation
SES AI Corporation (NYSE: SES) Investor Alert: Deadline in Lawsuit on June 26, 2 …
A deadline is coming up on June 26, 2026 in the lawsuit filed for certain investors of SES AI Corporation (NYSE: SES) over alleged securities laws violations by SES AI Corporation.
Investors who purchased shares of SES AI Corporation (NYSE: SES) have certain options and there are strict and short deadlines running. Deadline: June 26, 2026. SES AI Corporation (NYSE: SES) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Medpace Holdings, Inc. (NASDAQ: MEDP) Investor Alert: Deadline in Lawsuit on Jun …
A deadline is coming up on June 8, 2026 in the lawsuit filed for certain investors of Medpace Holdings, Inc. (NASDAQ: MEDP) over alleged securities laws violations by Medpace Holdings, Inc. (NASDAQ: MEDP).
Investors who purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP) have certain options and there are strict and short deadlines running. Deadline: June 8, 2026. Medpace Holdings, Inc. (NASDAQ: MEDP) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Enphase Energy, Inc. ( …
An investor, who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH), filed a lawsuit over alleged violations of Federal Securities Laws by Enphase Energy, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH) have certain options and for certain investors are short and strict deadlines running. Deadline: April 20, 2026. NASDAQ: ENPH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in shares of Fiserv, Inc. (NYSE: …
An investigation was announced for current long-term investors in shares of Fiserv, Inc. (NYSE: FI) concerning potential breaches of fiduciary duties by certain directors and officers of Fiserv, Inc.
Investors who are current long term investors in Fiserv, Inc. (NYSE: FI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
More Releases for Apellis
Eylea Market Future Business Opportunities 2025-2032 | Bayer AG, Bausch + Lomb, …
The Global Eylea Market is estimated to be valued at USD 838.6 Mn in 2025 and is expected to reach USD 673.7 Mn by 2032, declining at a negative compound annual growth rate (CAGR) of -3.1% from 2025 to 2032. This Eylea market size projection aligns with rising prevalence of diabetic retinopathy and age-related macular degeneration.
The ophthalmology therapeutics industry has been revolutionized by targeted anti-VEGF agents, with Eylea commanding a…
Dense Deposit Disease Market Forecasted to Surge in Coming Years, 2024-2034 Anal …
DelveInsight's "Dense Deposit Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dense Deposit Disease, historical and forecasted epidemiology as well as the Dense Deposit Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Dense Deposit Disease, offering comprehensive insights into the Dense Deposit Disease revenue trends,…
Complement 3 glomerulopathy Market: Epidemiology, Therapies, Companies, DelveIns …
Complement 3 glomerulopathy emerging therapies, such as Iptacopan (LNP023), Pegcetacoplan (APL-2), and others, are expected to boost the Complement 3 glomerulopathy Market in the upcoming years.
DelveInsight has launched a new report on "Complement 3 glomerulopathy - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Complement 3 glomerulopathy, historical and forecasted epidemiology as well as the Complement 3 glomerulopathy market trends in the United States, EU5…
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Is Booming So Rapidly | Nov …
The latest study released on the Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Paroxysmal Nocturnal Hemoglobinuria Treatment market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and…
Pegcetacoplan (APL-2) by Apellis Pharmaceuticals expected to drive market growth …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Pegcetacoplan (APL-2) (Apellis Pharmaceuticals) providing insights into the drug market landscape and market forecast of Pegcetacoplan (APL-2) upto 2032. The report, titled "Pegcetacoplan (APL-2) Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Pegcetacoplan (APL-2)…
Drug Delivery Partnering Terms and Agreements Market to See Major Growth by 2027 …
The Latest research study released by HTF MI "Drug Delivery Partnering Terms and Agreements Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered…
